January 29, 2020 / 6:16 AM / 25 days ago

Novartis Q4 core net income rises as Zolgensma, Cosentyx add to sales

ZURICH, Jan 29 (Reuters) - Novartis’s fourth-quarter core net income rose 13% in constant currencies, helped as its new Zolgensma gene therapy gained traction and five-year-old drugs Cosentyx and Entresto added to their blockbuster status.

Core net income rose to $2.99 billion while sales rose 9% to $12.4 billion. For 2020, the Swiss drugmaker expects net sales to grow in the mid-to high-single-digit percentage range, with core operating income expected to grow in the high-single to low-double-digit percentages. (Reporting by John Miller; Editing by Michael Shields)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below